Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries GeoVax Announces Upcoming Presentations at Scientific Conferences By: NewMediaWire May 04, 2022 at 09:00 AM EDT Atlanta, GA - (NewMediaWire) - May 04, 2022 - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer, announced today that it will be represented during presentations at the following upcoming scientific conferences.2022 National Biotechnology Conference, Anaheim, CA, May 9-12On May 11, Mary Hauser, PhD, GeoVax Director, Preclinical Research, will deliver a presentation titled, Strategic Prophylactics to Address Evolving SARS-CoV-2 Variants. Dr. Hauser will discuss the importance of T cell immunity to conserved viral epitopes amid the backdrop of rapid viral evolution. Genetic Vaccine Development for Infectious Disease Summit, Boston, MA, May 24-26On May 26, Don Diamond, PhD, professor in City of Hope’s Department of Hematology & Hematopoietic Transplantation, and the lead original developer of GeoVax’s vaccine against COVID-19 (GEO-CM04S1, formerly known as COH04S1) currently being evaluated in two Phase 2 clinical trials, will deliver a presentation titled, Conception, Construction, Pre-Clinical & Clinical Testing of COH04S1 Vaccine with Activity Against SARS-CoV-2.About GeoVaxGeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer using novel proprietary platforms. GeoVax’s product pipeline includes two ongoing Phase 2 clinical trials of GEO-CM04S1 (formerly COH04S1) for COVID-19 as a universal booster vaccine to mRNA vaccines authorized by the U.S. Food and Drug Administration (FDA) and as a primary vaccine for use in immunocompromised patients. In addition to GEO-CM04S1 for COVID-19, GeoVax is developing GEO-CM02 as a pan-coronavirus vaccine. The Company is also conducting a Phase 1/2 clinical trial of Gedeptin® for treatment of head and neck cancer. Gedeptin® has been granted orphan drug status by the FDA. Additional research and development programs include preventive vaccines against Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa) and malaria, as well as immunotherapies for multiple solid tumors. The Company’s portfolio of wholly owned, co-owned, and in-licensed intellectual property stands at over 70 granted or pending patent applications spread over 20 patent families.For additional information about GeoVax, visit our website: www.geovax.com.Contact:GeoVax Labs, Inc.investor@geovax.com678-384-7220View the original release on www.newmediawire.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
GeoVax Announces Upcoming Presentations at Scientific Conferences By: NewMediaWire May 04, 2022 at 09:00 AM EDT Atlanta, GA - (NewMediaWire) - May 04, 2022 - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer, announced today that it will be represented during presentations at the following upcoming scientific conferences.2022 National Biotechnology Conference, Anaheim, CA, May 9-12On May 11, Mary Hauser, PhD, GeoVax Director, Preclinical Research, will deliver a presentation titled, Strategic Prophylactics to Address Evolving SARS-CoV-2 Variants. Dr. Hauser will discuss the importance of T cell immunity to conserved viral epitopes amid the backdrop of rapid viral evolution. Genetic Vaccine Development for Infectious Disease Summit, Boston, MA, May 24-26On May 26, Don Diamond, PhD, professor in City of Hope’s Department of Hematology & Hematopoietic Transplantation, and the lead original developer of GeoVax’s vaccine against COVID-19 (GEO-CM04S1, formerly known as COH04S1) currently being evaluated in two Phase 2 clinical trials, will deliver a presentation titled, Conception, Construction, Pre-Clinical & Clinical Testing of COH04S1 Vaccine with Activity Against SARS-CoV-2.About GeoVaxGeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer using novel proprietary platforms. GeoVax’s product pipeline includes two ongoing Phase 2 clinical trials of GEO-CM04S1 (formerly COH04S1) for COVID-19 as a universal booster vaccine to mRNA vaccines authorized by the U.S. Food and Drug Administration (FDA) and as a primary vaccine for use in immunocompromised patients. In addition to GEO-CM04S1 for COVID-19, GeoVax is developing GEO-CM02 as a pan-coronavirus vaccine. The Company is also conducting a Phase 1/2 clinical trial of Gedeptin® for treatment of head and neck cancer. Gedeptin® has been granted orphan drug status by the FDA. Additional research and development programs include preventive vaccines against Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa) and malaria, as well as immunotherapies for multiple solid tumors. The Company’s portfolio of wholly owned, co-owned, and in-licensed intellectual property stands at over 70 granted or pending patent applications spread over 20 patent families.For additional information about GeoVax, visit our website: www.geovax.com.Contact:GeoVax Labs, Inc.investor@geovax.com678-384-7220View the original release on www.newmediawire.com
Atlanta, GA - (NewMediaWire) - May 04, 2022 - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer, announced today that it will be represented during presentations at the following upcoming scientific conferences.2022 National Biotechnology Conference, Anaheim, CA, May 9-12On May 11, Mary Hauser, PhD, GeoVax Director, Preclinical Research, will deliver a presentation titled, Strategic Prophylactics to Address Evolving SARS-CoV-2 Variants. Dr. Hauser will discuss the importance of T cell immunity to conserved viral epitopes amid the backdrop of rapid viral evolution. Genetic Vaccine Development for Infectious Disease Summit, Boston, MA, May 24-26On May 26, Don Diamond, PhD, professor in City of Hope’s Department of Hematology & Hematopoietic Transplantation, and the lead original developer of GeoVax’s vaccine against COVID-19 (GEO-CM04S1, formerly known as COH04S1) currently being evaluated in two Phase 2 clinical trials, will deliver a presentation titled, Conception, Construction, Pre-Clinical & Clinical Testing of COH04S1 Vaccine with Activity Against SARS-CoV-2.About GeoVaxGeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer using novel proprietary platforms. GeoVax’s product pipeline includes two ongoing Phase 2 clinical trials of GEO-CM04S1 (formerly COH04S1) for COVID-19 as a universal booster vaccine to mRNA vaccines authorized by the U.S. Food and Drug Administration (FDA) and as a primary vaccine for use in immunocompromised patients. In addition to GEO-CM04S1 for COVID-19, GeoVax is developing GEO-CM02 as a pan-coronavirus vaccine. The Company is also conducting a Phase 1/2 clinical trial of Gedeptin® for treatment of head and neck cancer. Gedeptin® has been granted orphan drug status by the FDA. Additional research and development programs include preventive vaccines against Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa) and malaria, as well as immunotherapies for multiple solid tumors. The Company’s portfolio of wholly owned, co-owned, and in-licensed intellectual property stands at over 70 granted or pending patent applications spread over 20 patent families.For additional information about GeoVax, visit our website: www.geovax.com.Contact:GeoVax Labs, Inc.investor@geovax.com678-384-7220View the original release on www.newmediawire.com